Distinct expression of CDCA3, CDCA5, and CDCA8 leads to shorter relapse free survival in breast cancer patient

Abstract

Breast cancer is a dangerous disease that results in high mortality rates for cancer patients. Many methods have been developed for the treatment and prevention of this disease. Determining the expression patterns of certain target genes in specific subtypes of breast cancer is important for developing new therapies for breast cancer. In the present study, we performed a holistic approach to screening the mRNA expression of six members of the cell division cycle-associated gene family (CDCA) with a focus on breast cancer using the Oncomine and The Cancer Cell Line Encyclopedia (CCLE) databases. Furthermore, Gene Expression-Based Outcome for Breast Cancer Online (GOBO) was also used to deeply mine the expression of each CDCA gene in clinical breast cancer tissue and breast cancer cell lines. Finally, the mRNA expression of the CDCA genes as related to breast cancer patient survival were analyzed using a Kaplan-Meier plot. CDCA3, CDCA5, and CDCA8 mRNA expression levels were significantly higher than the control sample in both clinical tumor sample and cancer cell lines. These highly expressed genes in the tumors of breast cancer patients dramatically reduced patient survival. The interaction network of CDCA3, CDCA5, and CDCA8 with their co-expressed genes also revealed that CDCA3 expression was highly correlated with cell cycle related genes such as CCNB2, CDC20, CDKN3, and CCNB1. CDCA5 expression was correlated with BUB1 and TRIP13, while CDCA8 expression was correlated with BUB1 and CCNB1. Altogether, these findings suggested CDCA3, CDCA5, and CDCA8 could have a high potency as targeted breast cancer therapies.

Construct ion of co - expression modules related to survival by WGCNA and identif ication of potential prognostic biomarkers in glioblastoma

“…The results showed that the OS probability of patients with high expression of CDCA5 and CDCA8 in tumor tissues was significantly decreased. This was consistent with the effect of the two on the survival time of patients in other types of tumors [30][31][32]. Secondly, we analyzed the correlation between the two and all genes involved in the p53 signaling pathway.…”

Identifying Tumorigenesis and Prognosis-Related Genes of Lung Adenocarcinoma: Based on Weighted Gene Coexpression Network Analysis

“…Up to now, there is no direct evidence that CDCA5 relates to the initiation and development of any subtype of lung cancer. However, the role of CDCA5 has been confirmed in other cancers including hepatocellular cancer [30], breast cancer [31], gastric cancer [32], and colorectal cancer [33]. Accumulating studies showed that increased CDCA5 level was a diagnostic biomarker and risk factor for numerous cancers which could enhance the tumor cells' capability of proliferation and metastasis by oncogenic ERK5-AP-1 pathway [33,34].…”

High-dimensional mediation analysis in survival models

“…For example, the gene H19 (cg21926276 locate) is related with both lung cancer and tumor growth, methylation of which has been thought as a sensitive marker of tobacco history [40,41]. The gene CDCA3 (cg27042065 located) is also associated with lung cancer and survival of cancer patients [42][43][44], and Song and Yang (2018) have reported that gene LOC338797 (cg26387355 located) is related with progression of tumor in lung cancer patients [45]. Besides confirming the previously reported genes, the three CpGs (cg21926276, cg27042065 and cg26387355) are also identified as novel markers for the survival of lung cancer patients.…”